Source Count: 11 | Weighted Score: 28 | Source Confidence: [3/5] | Primary Tier: 1 | Last Updated: March 11, 2026
Keywords: personalized medicine, precision medicine, pharmacogenomics, pharmacogenetics, biomarker, companion diagnostic, targeted therapy, genomic medicine, liquid biopsy, ctDNA, polygenic risk score, clinical sequencing, CYP450, HER2, BRCA, oncogenomics, immunotherapy, tumor profiling
Category Tags: future-technology, personalized-medicine, pharmacogenomics, precision-health, genomic-medicine
Cross-References: X_1_01 — Medicine Overview · S_2_10 — Gene Editing · Z_4_13 — Molecular Biology Overview

QUICK SUMMARY

Personalized medicine (also called precision medicine) tailors medical treatment to the individual characteristics of each patient — particularly their genetic makeup, but also incorporating biomarkers, environmental factors, lifestyle data, and molecular profiling. Rather than the traditional one-size-fits-all approach ("average patient" dosing and drug selection), personalized medicine seeks to deliver the right drug, at the right dose, to the right patient, at the right time. Pharmacogenomics — the study of how genetic variation affects drug response — is the most established pillar: variants in CYP450 enzymes (CYP2D6, CYP2C_5_04, CYP3A4) affect the metabolism of >80% of commonly prescribed drugs, making some patients poor metabolizers (risking toxicity) and others ultra-rapid metabolizers (risking therapeutic failure). The FDA now includes pharmacogenomic information on >300 drug labels. In oncology, personalized medicine is most advanced: tumor molecular profiling identifies actionable mutations (HER2 amplification → trastuzumab, EGFR mutations → erlotinib/osimertinib, BRAF V600E → vemurafenib, PD-L1 expression → immunotherapy), and companion diagnostics are required before prescribing many targeted therapies. Liquid biopsies — detecting circulating tumor DNA (ctDNA) in blood samples — enable non-invasive cancer monitoring, early detection, and treatment guidance. Beyond oncology, the Precision Medicine Initiative (US, 2015, now the All of Us Research Program) aims to enroll 1 million+ participants for long-term genomic and health data collection. Challenges include: cost and reimbursement, health equity (most genomic databases overrepresent European-ancestry populations), data privacy, clinical decision support integration, and proving that genomics-guided treatment improves outcomes over standard care in large-scale randomized trials.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Pharmacogenomics

• CYP450 enzyme variants: genetic polymorphisms in drug-metabolizing cytochrome P450 enzymes determine plasma drug levels:
• CYP2D6: metabolizes ~25% of commonly prescribed drugs (codeine, tamoxifen, SSRIs, beta-blockers); CYP2D6 has >100 allelic variants ranging from non-functional to ultra-rapid
• CYP2C19: metabolizes clopidogrel (antiplatelet), proton pump inhibitors, some antidepressants; poor metabolizers on clopidogrel face increased cardiovascular event risk — prompting FDA boxed warning
• DPYD: dihydropyrimidine dehydrogenase variants cause life-threatening toxicity from fluorouracil (5-FU) chemotherapy; preemptive testing increasingly standard
• Clinical Pharmacogenetics Implementation Consortium (CPIC): publishes evidence-based guidelines for >40 gene-drug pairs
• FDA pharmacogenomic labeling: >300 drug labels include genetic biomarker information

1.2 Oncology — Targeted Therapies

• Companion diagnostics: FDA-approved tests identifying patients likely to benefit from specific targeted therapies:
• HER2 testing (IHC, FISH) → trastuzumab (Herceptin) for HER2+ breast cancer
• EGFR mutation testing → erlotinib, osimertinib for non-small-cell lung cancer
• BRAF V600E → vemurafenib, dabrafenib for melanoma
• ALK rearrangements → crizotinib, alectinib for lung cancer
• PD-L1 expression and microsatellite instability (MSI) → immune checkpoint inhibitors (pembrolizumab)
• Comprehensive genomic profiling: panels like FoundationOne CDx sequence hundreds of cancer-related genes simultaneously to identify actionable mutations

1.3 Liquid Biopsy

• Circulating tumor DNA (ctDNA): fragments of tumor DNA shed into blood; detectable via next-generation sequencing:
• FDA-approved: Guardant360 CDx, FoundationOne Liquid CDx for identifying targetable mutations when tissue biopsy is unavailable
• Applications: treatment selection, monitoring response and resistance, detecting minimal residual disease (MRD) after surgery

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Polygenic Risk Scores

• Polygenic risk scores (PRS): aggregate the effects of thousands to millions of common genetic variants to estimate individual disease risk (coronary artery disease, type 2 diabetes, breast cancer, Alzheimer's):
• Can identify individuals at >3× population average risk, potentially enabling earlier screening and prevention
• Limitations: most PRS models are developed in European-ancestry populations and perform poorly in other populations — a significant health equity concern (Martin et al., 2019)
• Clinical utility is debated: whether knowing PRS changes patient behavior or clinical outcomes is an open question in ongoing trials

2.2 The All of Us Research Program

• NIH All of Us (launched 2018): aims to enroll 1 million+ diverse US participants contributing genomic data, electronic health records, wearable device data, surveys, and biospecimens — building a comprehensive resource for precision medicine research
• As of 2024: >750,000 enrolled, >400,000 with whole-genome sequencing data released to researchers

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Personalized Medicine for All Diseases

• While precision approaches are well-established in oncology and pharmacogenomics, extending personalized medicine to complex, polygenic, and environmentally influenced conditions (mental health, autoimmune diseases, cardiovascular disease) is far more challenging. Whether genomics-guided treatment will deliver clinically meaningful improvements over standard care for most common diseases remains to be demonstrated at scale

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Direct-to-Consumer Genetic Tests Provide Clinical-Grade Health Predictions

• [MISLEADING] DTC tests (e.g., 23andMe health reports) provide limited pharmacogenomic and disease risk information, but they are not equivalent to clinical-grade testing. Results are often based on a subset of known variants with limited sensitivity, and without genetic counseling, consumers may misinterpret risk information — potentially leading to unnecessary anxiety or false reassurance

COUNTER-ARGUMENTS

• Clinical utility limitations: a 2019 review by Murray et al. (Genetics in Medicine) found that whole-genome sequencing in unselected populations produces a high rate of variants of uncertain significance (VUS) that cannot guide clinical decisions and may cause patient anxiety without benefit — the gap between sequencing capability and interpretive knowledge remains substantial
• Health disparities risk: Keolu Fox (UC San Diego) and Alice Popejoy (Stanford, 2016, Nature) have documented that genomic databases are overwhelmingly derived from European-ancestry populations (~80%), meaning pharmacogenomic and risk prediction models have significantly lower accuracy for non-European groups — precision medicine may therefore widen health disparities rather than reduce them

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Collins, Francis S.; Harold Varmus | 2015 | "A New Initiative on Precision Medicine" | New England Journal of Medicine | ∅ | 372.9::793–795 | ∅ | ∅ | doi:10.1056/nejmp1500523 | ∅ | ∅ | ∅
2. Relling, Mary V.; William E | 2015 | "Pharmacogenomics in the Clinic" | Nature | ∅ | 526::343–350 | Evans | ∅ | doi:10.1038/nature15817 | ∅ | ∅ | ∅
3. Caudle, Kelly E., et al | 2020 | "Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendation from a Clinical Pharmacogenetics Implementation Consortium" | Clinical and Translational Science | ∅ | 13.1::116–124 | ∅ | ∅ | doi:10.1111/cts.12692 | ∅ | ∅ | ∅
4. Schilsky, Richard L | 2014 | "Implementing Personalized Cancer Care" | Nature Reviews Clinical Oncology | ∅ | 11::432–438 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
5. Wan, Jonathan C.M., et al | 2017 | "Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA" | Nature Reviews Cancer | ∅ | 17::223–238 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
6. Martin, Alicia R., et al | 2019 | "Clinical Use of Current Polygenic Risk Scores May Exacerbate Health Disparities" | Nature Genetics | ∅ | 51::584–591 | ∅ | ∅ | doi:10.1038/s41588-019-0379-x | ∅ | ∅ | ∅
7. Khera, Amit V., et al | 2018 | "Genome-Wide Polygenic Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations" | Nature Genetics | ∅ | 50::1219–1224 | ∅ | ∅ | doi:10.1038/s41588-018-0183-z | ∅ | ∅ | ∅
8. All of Us Research Program Investigators | 2019 | "The 'All of Us' Research Program" | New England Journal of Medicine | ∅ | 381::668–676 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Hyman, David M., et al | 2017 | "Implementing Genome-Driven Oncology" | Cell | ∅ | 168.4::584–599 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Pirmohamed, Munir | 2023 | "Pharmacogenomics: Current Status and Future Perspectives" | Nature Reviews Genetics | ∅ | 24::350–362 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. FDA (corp.) | 2024 | "Table of Pharmacogenomic Biomarkers in Drug Labeling" | ∅ | ∅ | ∅ | Silver Spring, MD: US Food and Drug Administration | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026